OSO BIOPHARMACEUTICALS MANUFACTURING
OSO BIOPHARMACEUTICALS MANUFACTURING
Social Links:
Founded:
2008-01-01
Address:
Albuquerque, New Mexico, United States
Country:
United States
Website Url:
http://www.osobio.com
Total Employee:
251+
Status:
Active
Contact:
505-345-0500
Email Addresses:
[email protected]
Technology used in webpage:
SPF Domain Not Resolving Amazon GoDaddy DNS AWS Global Accelerator GoDaddy Premium DNS Cisco Ironport Cloud
Similar Organizations
Bionavigen
Bionavigen is a biopharmaceutical company.
Fiplate
Fiplate is a biopharmaceutical company.
Official Site Inspections
http://www.osobio.com
- Host name: aec037177372cc6cd.awsglobalaccelerator.com
- IP address: 15.197.225.128
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Oso Biopharmaceuticals Manufacturing"
OrsoBio - Crunchbase Company Profile & Funding
OrsoBio is a clinical-stage biopharmaceutical company that creates therapies for patients suffering from severe metabolic disorders such as diabetes, severe dyslipidemia, lipodystrophies, and others. OrsoBio is committed to restoring …See details»
Orsobio, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Orsobio, Inc. with its drug pipeline, therapeutic area, technology platform, 4 clinical trials, 24 news, and 3 literature, Disease Domain:Endocrinology and Metabolic Disease, Technology …See details»
OsoBio - Company Profile - Tracxn
Oct 11, 2024 OsoBio - CMO specializing in injectables and lyophilized biological and pharmaceutical products. Acquired by Curia. Raised funding from 1 investor. OsoBio has 167 …See details»
OrsoBio Company Profile 2024: Valuation, Funding
OrsoBio General Information Description. Operator of a clinical-stage biopharmaceutical company intended to develop therapies for organ dysfunction. The company develops therapies to treat obesity and obesity-associated …See details»
OrsoBio - Overview, News & Similar companies | ZoomInfo.com
Who is OrsoBio. OrsoBio is a clinical-stage biopharmaceutical company developing first-in-class therapies to address the underlying causes of organ dysfunction in patients with severe …See details»
OsoBio at CMOLocator
Is this your Organization? Request Access. Locations. Albuquerque, NM 4401 Alexander Boulevard, NE Albuquerque, NM 87107 United States, North America. Contacts. Milton Boyer …See details»
OrsoBio - Funding, Financials, Valuation & Investors - Crunchbase
Nov 2, 2022 OrsoBio is a clinical-stage biopharmaceutical company that develops therapies to treat severe metabolic disorders. Search Crunchbase. Start Free Trial . ... How much funding …See details»
OrsoBio - Contacts, Employees, Board Members, Advisors & Alumni
Organization. OrsoBio . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Highlights. Employee Profiles 1. ... OrsoBio has 4 board members and …See details»
Obesity drug startup raises $67M; Vor’s ‘shielded transplant’ shows ...
Sep 6, 2024 OrsoBio, an obesity-focused startup backed by Eli Lilly, has raised $67 million in a Series B funding round, the company announced Friday. The cash will help advance a …See details»
OrsoBio Announces Phase 1 Trial of TLC-6740, a Mitochondrial ...
PALO ALTO, Calif.–(BUSINESS WIRE)– OrsoBio, Inc., a clinical-stage biopharmaceutical company developing treatments for severe metabolic disorders, today announced completion …See details»
OrsoBio - Updates, News, Events, Signals & Triggers - Crunchbase
Organization. OrsoBio . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Growth Insight Details. ... OrsoBio presented data on its liver-targeted …See details»
TLC-065 - Drug Targets, Indications, Patents - Synapse - Patsnap
-- Company to share clinical and preclinical data on ACC2, LXR, mitochondrial protonophore, and ACMSD programs -- PALO ALTO, Calif.--(BUSINESS WIRE)-- OrsoBio, Inc., a clinical-stage …See details»
TLC-1235 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 TLC-1235: a Mitochondrial oxidative phosphorylation uncouplers Drug, Initially developed by Orsobio, Inc., Now, its global highest R&D status is Preclinical, Mechanism: …See details»
OsoBio - Altaris, LLC
Jun 2, 2014 OsoBio President Milton Boyer to serve as vice president of DCAT’s executive committee Albuquerque, NM Dec 17, 2013 – OsoBio has reaffirmed its long-standing …See details»
OrsoBio, Inc. - Crunchbase Company Profile & Funding
OrsoBio, Inc. is located in Palo Alto, California, United States. Who are OrsoBio, Inc. 's competitors? Alternatives and possible competitors to OrsoBio, Inc. may include KBP …See details»
TLC-6740 Oral Solution and TLC-6740 Tablet and Drug ... - ICH GCP
Apr 7, 2023 November 26, 2024 updated by: OrsoBio, Inc A Phase 1/1b Study of Single and Multiple Ascending Doses of TLC 6740 in Healthy Subjects, Including Evaluation of Food …See details»
OrsoBio - Crunchbase
Organization. OrsoBio . Connect to CRM . Save . Summary. Financials. People. Signals & News. Similar Companies. Similar Companies. Edit Similar Companies Section. OrsoBio, Verismo …See details»
OrsoBio, Inc. - Contacts, Employees, Board Members ... - Crunchbase
OrsoBio, Inc. has 1 current employee profile, Co-Founder, Chief Business and Financial Officer Gangadhara Ganapati. Gangadhara Ganapati Co-Founder, Chief Business and Financial …See details»
TLC-6740 - Drug Targets, Indications, Patents - Synapse - Patsnap
Nov 21, 2024 TLC-6740: a Mitochondrial oxidative phosphorylation uncouplers Drug, Initially developed by Orsobio, Inc., Now, its global highest R&D status is Phase 1, Mechanism: …See details»